TrialThe Lancet. Neurology2018
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Scott E Kasner et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
61 papers cite itlatest 60 shown
this paperpooled itcites it